Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

September 21, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Cataract Surgery
Interventions
DRUG

DE-108

Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.

DRUG

Levofloxacin 0.5%

Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.

Trial Locations (6)

Unknown

Kyungpook National University Hospital, Kyungpook

Asan Medical Center, Seoul

Kim's eye Hospital, Seoul

Seoul National University Bundang Hospital, Seoul

Seoul Saint Marry's Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT02573610 - Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery | Biotech Hunter | Biotech Hunter